Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Patent metadata

Field	Value
Publication number	US-11839596-B2
Application number	US-202117469745-A
Country	US
Kind code	B2
Filing date	Sep 8, 2021
Priority date	Jan 9, 2013
Publication date	Dec 12, 2023
Grant date	Dec 12, 2023

Abstract

Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt or ester thereof and a pharmaceutically effective amount of exosomes and a pharmaceutically acceptable carrier, wherein the exosomes are isolated from a mesenchymal stem cell culture comprising mesenchymal stem cells and treprostinil or a pharmaceutically acceptable salt or ester thereof, wherein the treprostinil or pharmaceutically acceptable salt or ester thereof is present in an amount sufficient to increase the amount of vascular endothelial growth factor contained in the mesenchymal stem cell culture and wherein the exosomes have increased VEGF-A gene transcript levels relative to exosomes obtained from a mesenchymal stem cell culture to which a prostacyclin was not added during culturing.

2. The pharmaceutical composition of claim 1 , wherein the amount of the treprostinil or pharmaceutically acceptable salt or ester thereof added to the culture medium is between about 200 μg/mL and about 300 μg/mL.

3. The pharmaceutical composition of claim 1 , wherein the mesenchymal stem cell is obtained from bone marrow.

4. The pharmaceutical composition of claim 1 , wherein the mesenchymal stem cell is a mesenchymal precursor cell.

5. The pharmaceutical composition of claim 1 , wherein the exosomes have at least about 4-fold increased VEGF-A gene transcript levels relative to exosomes obtained from a mesenchymal stem cell culture to which a prostacyclin was not added during culturing.

6. The pharmaceutical composition of claim 1 , wherein the exosomes have diameter from about 150 nm to about 200 nm.

7. The pharmaceutical composition of claim 1 , wherein about 60% of the exosomes have diameter of about 200 nm.

Assignees

• United Therapeutics Corp

Inventors

• Jeffs Roger
• Petersen Thomas
• Ilagan Roger M
• Wade Michael

Classifications

• A61K31/5585 Primary

  having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61K31/192 Primary

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title